AI Engines For more Details: Perplexity Kagi Labs You
Blood Pressure Reduction: Bendroflumethiazide helps lower blood pressure by promoting the excretion of excess sodium and water through the kidneys, leading to decreased blood volume and reduced pressure within the blood vessels. By reducing blood pressure, bendroflumethiazide helps lower the risk of cardiovascular events such as heart attacks, strokes, and kidney damage associated with hypertension.
Edema Management: Thiazide diuretics like bendroflumethiazide are effective in reducing edema by increasing urine production and reducing fluid accumulation in the body. This can be beneficial for individuals with conditions such as congestive heart failure, liver cirrhosis, and kidney disorders, where fluid retention may occur.
Antihypertensive Effects: In addition to its diuretic effect, bendroflumethiazide may exert antihypertensive effects through other mechanisms, such as vasodilation and modulation of vascular tone. By promoting relaxation of the blood vessels, bendroflumethiazide helps improve blood flow and reduce peripheral resistance, contributing to its blood pressure-lowering effects.
Potassium and Electrolyte Balance: While bendroflumethiazide promotes the excretion of sodium and water, it also increases the excretion of potassium. Therefore, patients taking bendroflumethiazide may be at risk of developing hypokalemia (low potassium levels), which can lead to symptoms such as muscle weakness, fatigue, and cardiac arrhythmias. Monitoring of potassium levels and supplementation may be necessary in some cases.
Metabolic Effects: Thiazide diuretics like bendroflumethiazide can affect glucose and lipid metabolism. They may increase blood glucose levels and impair glucose tolerance, particularly in patients with diabetes or prediabetes. Additionally, thiazides may elevate serum lipid levels, including cholesterol and triglycerides, although the clinical significance of this effect remains debated.
Renal Function: Bendroflumethiazide may have renal protective effects in certain populations, particularly individuals with chronic kidney disease and proteinuria (excess protein in the urine). By reducing blood pressure and intraglomerular pressure, bendroflumethiazide helps slow the progression of kidney damage and preserve renal function over time.
Side Effects: Common side effects associated with bendroflumethiazide include dizziness, lightheadedness, headache, gastrointestinal upset, and electrolyte imbalances. Rare but serious adverse effects may include severe hypokalemia, hyponatremia (low sodium levels), hyperuricemia (elevated uric acid levels), and allergic reactions.
Interactions: Bendroflumethiazide may interact with other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, lithium, and certain antidiabetic medications. These interactions can affect the efficacy and safety of bendroflumethiazide and may require dosage adjustments or monitoring.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 2.9 | 0.3 | 8.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3 | 1.4 | 1.14 |
| Allergies | 3.7 | 0.9 | 3.11 |
| Allergy to milk products | 0.8 | 1.6 | -1 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 3.5 | 3.7 | -0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.5 | 3.6 |
| Ankylosing spondylitis | 3 | 1.1 | 1.73 |
| Anorexia Nervosa | 1 | 2.1 | -1.1 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 3.8 | 1.8 | 1.11 |
| Atherosclerosis | 1.7 | 0.9 | 0.89 |
| Atrial fibrillation | 2.9 | 1.9 | 0.53 |
| Autism | 5.2 | 5.6 | -0.08 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 1.3 | 0.8 | 0.63 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.5 | 0.5 | |
| Cancer (General) | 0.9 | 0.4 | 1.25 |
| Carcinoma | 3.1 | 1.9 | 0.63 |
| Celiac Disease | 2.3 | 2.2 | 0.05 |
| Cerebral Palsy | 1.2 | 0.8 | 0.5 |
| Chronic Fatigue Syndrome | 2.5 | 2.9 | -0.16 |
| Chronic Kidney Disease | 2.7 | 0.9 | 2 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.7 | 1.4 | 0.21 |
| Chronic Urticaria (Hives) | 1.6 | 0.5 | 2.2 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 0.8 | 1.25 |
| Cognitive Function | 2.4 | 1.4 | 0.71 |
| Colorectal Cancer | 6.1 | 2.1 | 1.9 |
| Constipation | 1.1 | 0.5 | 1.2 |
| Coronary artery disease | 2.1 | 2.1 | 0 |
| COVID-19 | 4.3 | 4.1 | 0.05 |
| Crohn's Disease | 6 | 3.5 | 0.71 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 1 | 1.1 | -0.1 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.1 | 1.1 | 0.91 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 6.1 | 4.8 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 1.1 | 0.82 |
| Endometriosis | 2.9 | 1.6 | 0.81 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.6 | 1.2 | 1.17 |
| erectile dysfunction | 1.8 | 0.3 | 5 |
| Fibromyalgia | 2.1 | 0.7 | 2 |
| Functional constipation / chronic idiopathic constipation | 3.4 | 2 | 0.7 |
| gallstone disease (gsd) | 3.3 | 1.1 | 2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 0.3 | 3.67 |
| Generalized anxiety disorder | 2.4 | 1.5 | 0.6 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0 | 0 |
| Graves' disease | 1.3 | 2.3 | -0.77 |
| Gulf War Syndrome | 0.3 | 0.8 | -1.67 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.7 | 0.6 | 3.5 |
| Heart Failure | 2.7 | 1.1 | 1.45 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1 | 0.3 | 2.33 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0 | 0 |
| hyperglycemia | 1.7 | 1.1 | 0.55 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypertension (High Blood Pressure | 2.7 | 2.3 | 0.17 |
| Hypothyroidism | 0 | 0.3 | 0 |
| Hypoxia | 2.6 | 0.3 | 7.67 |
| IgA nephropathy (IgAN) | 1.3 | 1.8 | -0.38 |
| Inflammatory Bowel Disease | 4.6 | 4 | 0.15 |
| Insomnia | 1.5 | 1.8 | -0.2 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 4.5 | 2.6 | 0.73 |
| ischemic stroke | 2.1 | 1.7 | 0.24 |
| Liver Cirrhosis | 5.2 | 3.7 | 0.41 |
| Long COVID | 4 | 3.1 | 0.29 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 0.6 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.3 | 2.33 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.8 | 1.7 | -1.13 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.6 | -1 |
| Metabolic Syndrome | 5 | 4.7 | 0.06 |
| Mood Disorders | 4.9 | 3.5 | 0.4 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 3.2 | 3.1 | 0.03 |
| Multiple system atrophy (MSA) | 0.5 | 0.3 | 0.67 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.8 | -1.8 | |
| Neuropathy (all types) | 0.3 | 1.6 | -4.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 1.8 | 0.94 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 6 | 5.2 | 0.15 |
| obsessive-compulsive disorder | 3.2 | 2.6 | 0.23 |
| Osteoarthritis | 2 | 0.9 | 1.22 |
| Osteoporosis | 1.7 | 1.2 | 0.42 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 4.4 | 4.6 | -0.05 |
| Polycystic ovary syndrome | 4.2 | 1.7 | 1.47 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 1.2 | 0.7 | 0.71 |
| Primary sclerosing cholangitis | 2 | 1.1 | 0.82 |
| Psoriasis | 2.1 | 1.8 | 0.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 3.3 | 0.21 |
| Rosacea | 0.3 | 0.8 | -1.67 |
| Schizophrenia | 2.5 | 1.9 | 0.32 |
| scoliosis | 0.4 | 0.4 | |
| Sjögren syndrome | 1.9 | 2 | -0.05 |
| Sleep Apnea | 1.2 | 0.8 | 0.5 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.1 | 15 |
| Stress / posttraumatic stress disorder | 2.9 | 1.6 | 0.81 |
| Systemic Lupus Erythematosus | 3.4 | 1.4 | 1.43 |
| Tic Disorder | 0.8 | 0.9 | -0.13 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.2 | 2.1 | 0.05 |
| Type 2 Diabetes | 5.8 | 4.7 | 0.23 |
| Ulcerative colitis | 4.1 | 2.9 | 0.41 |
| Unhealthy Ageing | 3.1 | 1.9 | 0.63 |
| Vitiligo | 1.7 | 0.7 | 1.43 |
